Targeting regulatory T cells by Curcumin: A potential for cancer immunotherapy.

[1]  S. Atkin,et al.  Current evidence and future perspectives for curcumin and its analogues as promising adjuncts to oxaliplatin: state‐of‐the‐art , 2019, Pharmacological research.

[2]  Shrikant Pawar,et al.  Curcumin in combination with anti‐cancer drugs: A nanomedicine review , 2019, Pharmacological research.

[3]  B. Baradaran,et al.  Immune checkpoint blockade opens a new way to cancer immunotherapy , 2018, Journal of cellular physiology.

[4]  H. Mirzaei,et al.  Chemopreventive and therapeutic potential of curcumin in esophageal cancer: Current and future status , 2018, International journal of cancer.

[5]  M. Najafi,et al.  Adjuvant chemotherapy with melatonin for targeting human cancers: A review , 2018, Journal of cellular physiology.

[6]  L. Yubao,et al.  Exosomal KLF3-AS1 from hMSCs promoted cartilage repair and chondrocyte proliferation in osteoarthritis. , 2018 .

[7]  G. Freeman,et al.  Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response , 2018, Nature Medicine.

[8]  Mingyao Liu,et al.  Inhibition of Rspo-Lgr4 Facilitates Checkpoint Blockade Therapy by Switching Macrophage Polarization. , 2018, Cancer research.

[9]  Jae-Hoon Chang,et al.  Regulatory T cell‐targeted hybrid nanoparticles combined with immuno‐checkpoint blockage for cancer immunotherapy , 2018, Journal of controlled release : official journal of the Controlled Release Society.

[10]  S. Lucas,et al.  Proton irradiation orchestrates macrophage reprogramming through NFκB signaling , 2018, Cell Death & Disease.

[11]  T. Fujiwara,et al.  Cancer-Associated Fibroblasts Affect Intratumoral CD8+ and FoxP3+ T Cells Via IL6 in the Tumor Microenvironment , 2018, Clinical Cancer Research.

[12]  A. Mollica,et al.  Integration of in vitro and in silico perspectives to explain chemical characterization, biological potential and anticancer effects of Hypericum salsugineum: A pharmacologically active source for functional drug formulations , 2018, PloS one.

[13]  J. Bluestone,et al.  Targeting EZH2 Reprograms Intratumoral Regulatory T Cells to Enhance Cancer Immunity , 2018, Cell reports.

[14]  Li Liu,et al.  Curcumin enhances anti-tumor immune response in tongue squamous cell carcinoma. , 2018, Archives of oral biology.

[15]  Xu Wang,et al.  miR-153 suppresses IDO1 expression and enhances CAR T cell immunotherapy , 2018, Journal of Hematology & Oncology.

[16]  S. Ziegler,et al.  KAP1 Regulates Regulatory T Cell Function and Proliferation in Both Foxp3-Dependent and -Independent Manners , 2018, Cell reports.

[17]  D. Noonan,et al.  Contribution to Tumor Angiogenesis From Innate Immune Cells Within the Tumor Microenvironment: Implications for Immunotherapy , 2018, Front. Immunol..

[18]  R. Rosell,et al.  STAT3 as a potential immunotherapy biomarker in oncogene-addicted non-small cell lung cancer , 2018, Therapeutic advances in medical oncology.

[19]  Mei Liu,et al.  IL-6 influences the polarization of macrophages and the formation and growth of colorectal tumor , 2018, Oncotarget.

[20]  J. Schlom,et al.  M7824, a novel bifunctional anti-PD-L1/TGFβ Trap fusion protein, promotes anti-tumor efficacy as monotherapy and in combination with vaccine , 2018, Oncoimmunology.

[21]  A. Sahebkar,et al.  Therapeutic effects of curcumin in inflammatory and immune‐mediated diseases: A nature‐made jack‐of‐all‐trades? , 2018, Journal of cellular physiology.

[22]  Z. Werb,et al.  Innate and acquired immune surveillance in the postdissemination phase of metastasis , 2018, The FEBS journal.

[23]  Haoshuai Zhu,et al.  Curcumin converts Foxp3+ regulatory T cells to T helper 1 cells in patients with lung cancer , 2018, Journal of cellular biochemistry.

[24]  Weimin Yin,et al.  Dual-targeting biomimetic delivery for anti-glioma activity via remodeling the tumor microenvironment and directing macrophage-mediated immunotherapy , 2018, Chemical science.

[25]  Q. Qian,et al.  Cancer vaccine: learning lessons from immune checkpoint inhibitors , 2018, Journal of Cancer.

[26]  A. Batista-Duharte,et al.  Molecular adjuvants that modulate regulatory T cell function in vaccination: A critical appraisal , 2017, Pharmacological research.

[27]  Tingyi Sun.  Long noncoding RNAs act as regulators of autophagy in cancer , 2017, Pharmacological research.

[28]  E. Tapia,et al.  Interleukin 10 (IL10) proximal promoter polymorphisms beyond clinical response in classical Hodgkin lymphoma: Exploring the basis for the genetic control of the tumor microenvironment , 2017, Oncoimmunology.

[29]  Bahman Rashidi,et al.  MicroRNA: A novel target of curcumin in cancer therapy , 2017, Journal of cellular physiology.

[30]  P. Rochaix,et al.  TNFα blockade overcomes resistance to anti-PD-1 in experimental melanoma , 2017, Nature Communications.

[31]  A. Necchi,et al.  Current markers and their value in the era of immuno-oncology , 2017, Translational andrology and urology.

[32]  G. Dworacki,et al.  The Dual Role of Treg in Cancer , 2017, Scandinavian journal of immunology.

[33]  R. Rajmani,et al.  Apoptotic and Immunosuppressive Effects of Turmeric Paste on 7, 12 Di Methyl Benz (a) Anthracene Induced Skin Tumor Model of Wistar Rat , 2017, Nutrition and cancer.

[34]  M. Kawahara,et al.  Nanoparticle curcumin ameliorates experimental colitis via modulation of gut microbiota and induction of regulatory T cells , 2017, PloS one.

[35]  J. González‐Gallego,et al.  Melatonin enhances sorafenib actions in human hepatocarcinoma cells by inhibiting mTORC1/p70S6K/HIF-1α and hypoxia-mediated mitophagy , 2017, Oncotarget.

[36]  G. D’Orazi,et al.  Chloroquine supplementation increases the cytotoxic effect of curcumin against Her2/neu overexpressing breast cancer cells in vitro and in vivo in nude mice while counteracts it in immune competent mice , 2017, Oncoimmunology.

[37]  Zhong Wang,et al.  Bisdemethoxycurcumin in combination with α-PD-L1 antibody boosts immune response against bladder cancer , 2017, OncoTargets and therapy.

[38]  Amirhosein Sahebkar,et al.  Curcumin as a multifaceted compound against human papilloma virus infection and cervical cancers: A review of chemistry, cellular, molecular, and preclinical features , 2017, BioFactors.

[39]  Bin Xu,et al.  Curcumin up regulates T helper 1 cells in patients with colon cancer. , 2017, American journal of translational research.

[40]  G. Sa,et al.  New insights into therapeutic activity and anticancer properties of curcumin , 2017, Journal of experimental pharmacology.

[41]  A. Sahebkar,et al.  Curcumin as a natural regulator of monocyte chemoattractant protein-1. , 2017, Cytokine & growth factor reviews.

[42]  R. Weinberg,et al.  Emerging Biological Principles of Metastasis , 2017, Cell.

[43]  S. Chouaib,et al.  Hypoxic stress: obstacles and opportunities for innovative immunotherapy of cancer , 2017, Oncogene.

[44]  L. Lum,et al.  Cancer Immunology and Immunotherapy. , 2016, Anticancer research.

[45]  A. Sahebkar,et al.  Curcumin: A new candidate for melanoma therapy? , 2016, International journal of cancer.

[46]  Z. Zuo,et al.  Combined therapy using bevacizumab and turmeric ethanolic extract (with absorbable curcumin) exhibited beneficial efficacy in colon cancer mice. , 2016, Pharmacological research.

[47]  Huining He,et al.  Curcumin based combination therapy for anti-breast cancer: from in vitro drug screening to in vivo efficacy evaluation , 2016, Frontiers of Chemical Science and Engineering.

[48]  A. Sahebkar,et al.  Difluorinated Curcumin: A Promising Curcumin Analogue with Improved Anti-Tumor Activity and Pharmacokinetic Profile. , 2016, Current pharmaceutical design.

[49]  L. Yue,et al.  Curcumin ameliorates experimental autoimmune myasthenia gravis by diverse immune cells , 2016, Neuroscience Letters.

[50]  Haimei Zhao,et al.  Curcumin improves regulatory T cells in gut-associated lymphoid tissue of colitis mice. , 2016, World journal of gastroenterology.

[51]  H. Feng,et al.  Curcumin reduces brain-infiltrating T lymphocytes after intracerebral hemorrhage in mice , 2016, Neuroscience Letters.

[52]  A. Sahebkar,et al.  Curcumin downregulates human tumor necrosis factor-α levels: A systematic review and meta-analysis ofrandomized controlled trials. , 2016, Pharmacological research.

[53]  Michael Loran Dustin.  Cancer immunotherapy: Killers on sterols , 2016, Nature.

[54]  Mandy A. Allison,et al.  Physician Attitudes toward Adult Vaccines and other Preventive Practices, United States, 2012 , 2016, Public health reports.

[55]  Yuhua Wang,et al.  Curcumin Micelles Remodel Tumor Microenvironment and Enhance Vaccine Activity in an Advanced Melanoma Model. , 2016, Molecular therapy : the journal of the American Society of Gene Therapy.

[56]  Tyler Hill,et al.  Inclusion of Strep-Tag II in design of antigen receptors for T cell immunotherapy , 2016, Nature Biotechnology.

[57]  R. Montironi,et al.  New toxicity profile for novel immunotherapy agents: focus on immune-checkpoint inhibitors , 2016, Expert opinion on drug metabolism & toxicology.

[58]  L. Meheus,et al.  Cryoablation and Meriva have strong therapeutic effect on triple-negative breast cancer , 2016, Oncoimmunology.

[59]  K. Kakimi,et al.  Advances in personalized cancer immunotherapy , 2016, Breast Cancer.

[60]  A. Sahebkar,et al.  Curcumin as a MicroRNA Regulator in Cancer: A Review. , 2016, Reviews of physiology, biochemistry and pharmacology.

[61]  A. Jemal,et al.  Cancer statistics, 2016 , 2016, CA: a cancer journal for clinicians.

[62]  J. Soria,et al.  Upcoming innovations in lung cancer immunotherapy: focus on immune checkpoint inhibitors. , 2015, Chinese clinical oncology.

[63]  E. Mittendorf,et al.  Cancer vaccines in the new era of cancer immunotherapy. , 2015, Vaccine.

[64]  J. Schellens,et al.  The use of combinations of monoclonal antibodies in clinical oncology. , 2015, Cancer treatment reviews.

[65]  N. Gül,et al.  Antibody-Dependent Phagocytosis of Tumor Cells by Macrophages: A Potent Effector Mechanism of Monoclonal Antibody Therapy of Cancer. , 2015, Cancer research.

[66]  R. Brentjens,et al.  Overcoming Antigen Escape with CAR T-cell Therapy. , 2015, Cancer discovery.

[67]  Melody A Swartz,et al.  Engineering opportunities in cancer immunotherapy , 2015, Proceedings of the National Academy of Sciences.

[68]  G. Sa,et al.  Curcumin and tumor immune-editing: resurrecting the immune system , 2015, Cell Division.

[69]  N. Shore.  Advances in the understanding of cancer immunotherapy , 2015, BJU international.

[70]  Nikhil S. Joshi,et al.  Regulatory T Cells in Tumor-Associated Tertiary Lymphoid Structures Suppress Anti-tumor T Cell Responses. , 2015, Immunity.

[71]  Yiping Yang,et al.  Cancer immunotherapy: harnessing the immune system to battle cancer. , 2015, The Journal of clinical investigation.

[72]  M. Banach,et al.  Effect of curcuminoids on oxidative stress: A systematic review and meta-analysis of randomized controlled trials , 2015 .

[73]  C. Borg,et al.  Interest of Tumor-Specific CD4 T Helper 1 Cells for Therapeutic Anticancer Vaccine , 2015, Vaccines.

[74]  S. Selvan,et al.  “Adherent” versus Other Isolation Strategies for Expanding Purified, Potent, and Activated Human NK Cells for Cancer Immunotherapy , 2015, BioMed research international.

[75]  D. Shin,et al.  Combination effect of regulatory T-cell depletion and ionizing radiation in mouse models of lung and colon cancer. , 2015, International journal of radiation oncology, biology, physics.

[76]  Xiangdong Wang,et al.  Regulatory T cells and potential inmmunotherapeutic targets in lung cancer , 2015, Cancer and Metastasis Reviews.

[77]  S. Kane,et al.  CD30 Downregulation, MMAE Resistance, and MDR1 Upregulation Are All Associated with Resistance to Brentuximab Vedotin , 2015, Molecular Cancer Therapeutics.

[78]  C. Drake,et al.  Immune checkpoint blockade: a common denominator approach to cancer therapy. , 2015, Cancer cell.

[79]  G. Sa,et al.  MEK inhibition prevents tumour‐shed transforming growth factor‐β‐induced T‐regulatory cell augmentation in tumour milieu , 2015, Immunology.

[80]  N. Restifo,et al.  The interplay of effector and regulatory T cells in cancer. , 2015, Current opinion in immunology.

[81]  Baoan Chen,et al.  Brentuximab vedotin for relapsed or refractory Hodgkin’s lymphoma , 2015, Drug design, development and therapy.

[82]  C. Mathers,et al.  Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012 , 2015, International journal of cancer.

[83]  P. Validire,et al.  CD8+CD103+ Tumor–Infiltrating Lymphocytes Are Tumor-Specific Tissue-Resident Memory T Cells and a Prognostic Factor for Survival in Lung Cancer Patients , 2015, The Journal of Immunology.

[84]  M. Thill.  New frontiers in oncology: biosimilar monoclonal antibodies for the treatment of breast cancer , 2015, Expert review of anticancer therapy.

[85]  G. Weiner,et al.  Cancer immunotherapy and breaking immune tolerance: new approaches to an old challenge. , 2015, Cancer research.

[86]  F. Tanaka,et al.  Regulatory T-cells and micrometastasis in lymph nodes of stage I NSCLC. , 2014, Anticancer research.

[87]  K. Priyadarsini.  The Chemistry of Curcumin: From Extraction to Therapeutic Agent , 2014, Molecules.

[88]  Z. Werb,et al.  Remodelling the extracellular matrix in development and disease , 2014, Nature Reviews Molecular Cell Biology.

[89]  D. Speiser,et al.  Cancer immunotherapy drives implementation science in oncology , 2014, Human vaccines & immunotherapeutics.

[90]  Antoni Ribas,et al.  Improved Survival with T Cell Clonotype Stability After Anti–CTLA-4 Treatment in Cancer Patients , 2014, Science Translational Medicine.

[91]  M. Tangney,et al.  Oral Tolerance to Cancer Can Be Abrogated by T Regulatory Cell Inhibition , 2014, PloS one.

[92]  Zhiqiang Liu,et al.  Mast cell-derived serine proteinase regulates T helper 2 polarization , 2014, Scientific Reports.

[93]  Marlus Chorilli,et al.  Nanotechnology-based drug delivery systems and herbal medicines: a review , 2013, International journal of nanomedicine.

[94]  B. Czerniecki,et al.  Inhibition of CD4+CD25+ Regulatory T Cell Function and Conversion into Th1-Like Effectors by a Toll-Like Receptor-Activated Dendritic Cell Vaccine , 2013, PloS one.

[95]  B. Aggarwal,et al.  Curcumin improves the therapeutic efficacy of Listeriaat-Mage-b vaccine in correlation with improved T-cell responses in blood of a triple-negative breast cancer model 4T1 , 2013, Cancer medicine.

[96]  R. Ordoñez,et al.  Inhibition of VEGF expression through blockade of Hif1α and STAT3 signalling mediates the anti-angiogenic effect of melatonin in HepG2 liver cancer cells , 2013, British Journal of Cancer.

[97]  T. Wu,et al.  Bortezomib enhances antigen-specific cytotoxic T cell responses against immune-resistant cancer cells generated by STAT3-ablated dendritic cells. , 2013, Pharmacological research.

[98]  Michael Kalos,et al.  T cell-based gene therapy of cancer. , 2013, Translational research : the journal of laboratory and clinical medicine.

[99]  K. Scharffetter-Kochanek,et al.  Reduced CD18 Levels Drive Regulatory T Cell Conversion into Th17 Cells in the CD18hypo PL/J Mouse Model of Psoriasis , 2013, The Journal of Immunology.

[100]  D. Dinh,et al.  Role of MMP-2 in the Regulation of IL-6/Stat3 Survival Signaling via Interaction With α5β1 Integrin in glioma , 2012, Oncogene.

[101]  D. Felsher,et al.  Tumor dormancy, oncogene addiction, cellular senescence, and self-renewal programs. , 2013, Advances in experimental medicine and biology.

[102]  T. Hagemann,et al.  The tumor microenvironment at a glance , 2012, Journal of Cell Science.

[103]  F. Marincola,et al.  Cancer classification using the Immunoscore: a worldwide task force , 2012, Journal of Translational Medicine.

[104]  Da-wei Wang,et al.  Curcumin inhibits suppressive capacity of naturally occurring CD4+CD25+ regulatory T cells in mice in vitro. , 2012, International immunopharmacology.

[105]  G. Zhai,et al.  Advances in nanotechnology-based delivery systems for curcumin. , 2012, Nanomedicine.

[106]  R. Scolyer,et al.  Tumor-infiltrating lymphocyte grade is an independent predictor of sentinel lymph node status and survival in patients with cutaneous melanoma. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[107]  P. Bhattacharyya,et al.  Death by design: where curcumin sensitizes drug-resistant tumours. , 2012, Anticancer research.

[108]  C. Sautès-Fridman,et al.  The immune contexture in human tumours: impact on clinical outcome , 2012, Nature Reviews Cancer.

[109]  Steven A. Rosenberg,et al.  Adoptive immunotherapy for cancer: harnessing the T cell response , 2012, Nature Reviews Immunology.

[110]  Drew M. Pardoll,et al.  The blockade of immune checkpoints in cancer immunotherapy , 2012, Nature Reviews Cancer.

[111]  F. Kraeber-Bodéré,et al.  Radiolabeled antibodies for cancer imaging and therapy. , 2012, Methods in molecular biology.

[112]  S. Bhattacharyya,et al.  Curcumin: the multi-targeted therapy for cancer regression. , 2012, Frontiers in bioscience.

[113]  J. Teillaud.  From whole monoclonal antibodies to single domain antibodies: think small. , 2012, Methods in molecular biology.

[114]  Stefano Caserta,et al.  Central and effector memory CD4 and CD8 T-cell responses to tumor-associated antigens. , 2012, Critical reviews in immunology.

[115]  B. Bonnotte,et al.  The Dendritic Cell-Regulatory T Lymphocyte Crosstalk Contributes to Tumor-Induced Tolerance , 2011, Clinical & developmental immunology.

[116]  S. Rosenberg,et al.  Treating cancer with genetically engineered T cells. , 2011, Trends in biotechnology.

[117]  Robert A. Weinberg,et al.  Tumor Metastasis: Molecular Insights and Evolving Paradigms , 2011, Cell.

[118]  Yi Zhang,et al.  Low-dose curcumin leads to the inhibition of tumor growth via enhancing CTL-mediated antitumor immunity. , 2011, International immunopharmacology.

[119]  G. D. de Bock,et al.  The prognostic influence of tumour-infiltrating lymphocytes in cancer: a systematic review with meta-analysis , 2011, British Journal of Cancer.

[120]  E. Srivatsan,et al.  Curcumin: A review of anti-cancer properties and therapeutic activity in head and neck squamous cell carcinoma , 2011, Molecular Cancer.

[121]  Y. Wan,et al.  An Intrinsic Mechanism Predisposes Foxp3-Expressing Regulatory T Cells to Th2 Conversion In Vivo , 2010, The Journal of Immunology.

[122]  G. Trinchieri,et al.  Tumor-specific CD8+ T cells expressing interleukin-12 eradicate established cancers in lymphodepleted hosts. , 2010, Cancer research.

[123]  W. Stetler-Stevenson,et al.  Matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs): Positive and negative regulators in tumor cell adhesion. , 2010, Seminars in cancer biology.

[124]  T. Schumacher,et al.  Development of adoptive cell therapy for cancer: a clinical perspective. , 2010, Human gene therapy.

[125]  T. Okazaki,et al.  Tumor cell expression of programmed cell death‐1 ligand 1 is a prognostic factor for malignant melanoma , 2010, Cancer.

[126]  S. Bhattacharyya,et al.  Curcumin reverses T cell-mediated adaptive immune dysfunctions in tumor-bearing hosts , 2010, Cellular and Molecular Immunology.

[127]  M. Karin,et al.  Immunity, Inflammation, and Cancer , 2010, Cell.

[128]  D. Mougiakakos,et al.  Regulatory T cells in cancer. , 2010, Advances in cancer research.

[129]  T. Das,et al.  Multifocal signal modulation therapy of cancer: ancient weapon, modern targets , 2010, Molecular and Cellular Biochemistry.

[130]  Loise M. Francisco,et al.  PD-L1 regulates the development, maintenance, and function of induced regulatory T cells , 2009, The Journal of experimental medicine.

[131]  Midori Takasaki,et al.  Cancer chemopreventive activity of the prenylated coumarin, umbelliprenin, in vivo , 2009, European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation.

[132]  Xiaohua Ma,et al.  Mechanisms of drug combinations: interaction and network perspectives , 2009, Nature Reviews Drug Discovery.

[133]  B. Aggarwal,et al.  Potential therapeutic effects of curcumin, the anti-inflammatory agent, against neurodegenerative, cardiovascular, pulmonary, metabolic, autoimmune and neoplastic diseases. , 2009, The international journal of biochemistry & cell biology.

[134]  B. Aggarwal,et al.  Biological activities of curcumin and its analogues (Congeners) made by man and Mother Nature. , 2008, Biochemical pharmacology.

[135]  T. Das,et al.  Anti cancer effects of curcumin: cycle of life and death , 2008, Cell Division.

[136]  A. Gemma,et al.  Predominant infiltration of macrophages and CD8+ T Cells in cancer nests is a significant predictor of survival in stage IV nonsmall cell lung cancer , 2008, Cancer.

[137]  Robert A Newman,et al.  Bioavailability of curcumin: problems and promises. , 2007, Molecular pharmaceutics.

[138]  M. Colombo,et al.  Regulatory T-cell inhibition versus depletion: the right choice in cancer immunotherapy , 2007, Nature Reviews Cancer.

[139]  G. Feldmann,et al.  Polymeric nanoparticle-encapsulated curcumin ("nanocurcumin"): a novel strategy for human cancer therapy , 2007, Journal of nanobiotechnology.

[140]  V. Reuter,et al.  CD8 tumor-infiltrating lymphocytes are predictive of survival in muscle-invasive urothelial carcinoma , 2007, Proceedings of the National Academy of Sciences.

[141]  A. Rudensky,et al.  Maintenance of the Foxp3-dependent developmental program in mature regulatory T cells requires continued expression of Foxp3 , 2007, Nature Immunology.

[142]  B. Aggarwal,et al.  Curcumin: the Indian solid gold. , 2007, Advances in experimental medicine and biology.

[143]  Z. Trajanoski,et al.  Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome , 2006, Science.

[144]  S. Hirohashi,et al.  Prevalence of FOXP3+ Regulatory T Cells Increases During the Progression of Pancreatic Ductal Adenocarcinoma and Its Premalignant Lesions , 2006, Clinical Cancer Research.

[145]  Ting-Chao Chou,et al.  Theoretical Basis, Experimental Design, and Computerized Simulation of Synergism and Antagonism in Drug Combination Studies , 2006, Pharmacological Reviews.

[146]  Daniel Normolle,et al.  Dose escalation of a curcuminoid formulation , 2006, BMC complementary and alternative medicine.

[147]  L. Platanias,et al.  Curcumin induces apoptosis via inhibition of PI3′-kinase/AKT pathway in Acute T cell Leukemias , 2006, Apoptosis.

[148]  T. Waldmann.  Effective cancer therapy through immunomodulation. , 2006, Annual review of medicine.

[149]  Rakesh K. Sharma,et al.  Delivery of hydrophobised 5-fluorouracil derivative to brain tissue through intravenous route using surface modified nanogels , 2006, Journal of drug targeting.

[150]  Gerd Ritter,et al.  Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[151]  M. Pirmohamed,et al.  Phase I Clinical Trial of Oral Curcumin , 2004, Clinical Cancer Research.

[152]  George Coukos,et al.  Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival , 2004, Nature Medicine.

[153]  A. Dennison,et al.  Detection of curcumin and its metabolites in hepatic tissue and portal blood of patients following oral administration , 2004, British Journal of Cancer.

[154]  S. Wojtowicz-Praga.  Reversal of Tumor-induced Immunosuppression by TGF-β Inhibitors , 2003, Investigational New Drugs.

[155]  K. Karimi,et al.  Paradoxical effects of interleukin‐10 on the maturation of murine myeloid dendritic cells , 2003, Immunology.

[156]  Kazuyoshi Takeda,et al.  New aspects of natural-killer-cell surveillance and therapy of cancer , 2002, Nature Reviews Cancer.

[157]  Thorsteinn Loftsson,et al.  Studies of curcumin and curcuminoids. XXVII. Cyclodextrin complexation: solubility, chemical and photochemical stability. , 2002, International journal of pharmaceutics.

[158]  Donald J L Jones,et al.  Metabolism of the cancer chemopreventive agent curcumin in human and rat intestine. , 2002, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[159]  S. Jee,et al.  Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions. , 2001, Anticancer research.

[160]  H Nagura,et al.  Proliferative activity of intratumoral CD8(+) T-lymphocytes as a prognostic factor in human renal cell carcinoma: clinicopathologic demonstration of antitumor immunity. , 2001, Cancer research.

[161]  M. Pirmohamed,et al.  Pharmacodynamic and pharmacokinetic study of oral Curcuma extract in patients with colorectal cancer. , 2001, Clinical Cancer Research.

[162]  R. Schreiber,et al.  IFNγ and lymphocytes prevent primary tumour development and shape tumour immunogenicity , 2001, Nature.

[163]  K. Vousden,et al.  PUMA, a novel proapoptotic gene, is induced by p53. , 2001, Molecular cell.

[164]  L. Howells,et al.  Characterization of metabolites of the chemopreventive agent curcumin in human and rat hepatocytes and in the rat in vivo, and evaluation of their ability to inhibit phorbol ester-induced prostaglandin E2 production. , 2001, Cancer research.

[165]  R. Schreiber,et al.  Eradication of established tumors by CD8+ T cell adoptive immunotherapy. , 2000, Immunity.

[166]  M. Bertagnolli,et al.  Inhibition of intestinal tumors by curcumin is associated with changes in the intestinal immune cell profile. , 2000, The Journal of surgical research.

[167]  D. Hanahan,et al.  The Hallmarks of Cancer , 2000, Cell.

[168]  A. Harris,et al.  Anticancer agents targeting signaling molecules and cancer cell environment: challenges for drug development? , 1999, Journal of the National Cancer Institute.

[169]  Spyros A. Kalams,et al.  The Critical Need for CD4 Help in Maintaining Effective Cytotoxic T Lymphocyte Responses , 1998, The Journal of experimental medicine.

[170]  A. Harris,et al.  Loss of antigen-presenting molecules (MHC class I and TAP-1) in lung cancer. , 1996, British Journal of Cancer.

[171]  W. Clark.  Tumour progression and the nature of cancer. , 1991, British journal of cancer.

[172]  V. Ravindranath,et al.  In vitro studies on the intestinal absorption of curcumin in rats. , 1981, Toxicology.

[173]  W. A. Fleming,et al.  The influence of adjuvants on the immunological response of the chicken. I. Effects on primary and secondary responses of various adjuvants in the primary stimulus. , 1970, Immunology.